S04 E02: Meet GOLD's new catalyst – AZ's Mina Makar
EMJ GOLD: Pharma news, views and analysis
00:00
CVRM - What's Next for CVRM?
I think about the unmet need in CVRM probably as much or more than almost any other disease. 50% of heart failure patients die within five years. CKD patients that are stage three and beyond, vast majority are still undiagnosed under treated. And so I'm really excited about the CVRM portfolio that we're building because I think it's probably broader than or as broad as anyone else in this industry across cardiovascular heart failure,. metabolic and so forth.
Play episode from 05:04
Transcript
